Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes

More than half of participants taking the highest dose achieved normal A1C levels, a key secondary endpoint in first phase 3 trial of SURPASS program Participants in this monotherapy study had relatively recently diagnosed diabetes, with a mean duration of 4.7 years INDIANAPOLIS , Dec.